Viking Therapeutics (VKTX) Net Cash Flow (2014 - 2026)

Viking Therapeutics has disclosed Net Cash Flow across 13 years of filings, most recently posting -$47.7 million for Q1 2026.

• Net Cash Flow for Q1 2026 came in at -$47.7 million, down 523.6% year-over-year; the trailing twelve-month figure through Mar 2026 was $80.2 million (up 150.89% YoY), and the FY2025 annual result was $139.1 million, up 584.95% from the prior year.
• Net Cash Flow came in at -$47.7 million for Q1 2026 at Viking Therapeutics, down from $65.4 million in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $140.1 million in Q1 2024 to a low of -$151.7 million in Q2 2024.
• The 5-year median for Net Cash Flow is $6.5 million (2024), against an average of $5.4 million.
• Across the five-year window, Net Cash Flow surged 1195.85% in 2023 and slumped 523.6% in 2026, its largest moves.
• Viking Therapeutics' Net Cash Flow stood at $7.1 million in 2022, then soared by 158.1% to $18.3 million in 2023, then slumped by 229.08% to -$23.6 million in 2024, then jumped by 377.26% to $65.4 million in 2025, then tumbled by 172.92% to -$47.7 million in 2026.
• The last three Net Cash Flow figures came in at -$47.7 million (Q1 2026), $65.4 million (Q4 2025), and $66.5 million (Q3 2025), per Business Quant data.